<SEC-DOCUMENT>0001193125-16-598293.txt : 20160523
<SEC-HEADER>0001193125-16-598293.hdr.sgml : 20160523
<ACCEPTANCE-DATETIME>20160523082438
ACCESSION NUMBER:		0001193125-16-598293
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160523
FILED AS OF DATE:		20160523
DATE AS OF CHANGE:		20160523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AEGON NV
		CENTRAL INDEX KEY:			0000769218
		STANDARD INDUSTRIAL CLASSIFICATION:	LIFE INSURANCE [6311]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-10882
		FILM NUMBER:		161667837

	BUSINESS ADDRESS:	
		STREET 1:		AEGONPLEIN 50
		STREET 2:		PO BOX 85
		CITY:			THE HAGUE
		STATE:			P7
		ZIP:			2501 CB
		BUSINESS PHONE:		011-31-70-344-7308

	MAIL ADDRESS:	
		STREET 1:		AEGONPLEIN 50
		STREET 2:		PO BOX 85
		CITY:			THE HAGUE
		STATE:			P7
		ZIP:			2501 CB
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d187719d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Securities and Exchange Commission
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of Foreign Issuer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule 13a-16 or 15d/16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>May 2016 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AEGON N.V.
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aegonplein 50 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2591 TV
THE HAGUE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Netherlands </B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aegon&#146;s press release, dated May&nbsp;23, 2016, is included as appendix and incorporated herein by
reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">AEGON N.V.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May 23, 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ J.O. van Klinken</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">J.O. van Klinken</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Executive Vice President and</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">General Counsel</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g187719snap1.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">The Hague &#150; May 23, 2016 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aegon divests remaining<B> </B>part of UK annuity portfolio </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aegon announces the sale of GBP 3 billion annuity liabilities to Legal &amp; General. This transaction follows the recently announced sale of GBP 6 billion of
its UK annuity portfolio and completes the divestment of Aegon&#146;s own annuity portfolio. Aegon now has approximately GBP 1 billion annuity liabilities remaining through an inward reinsurance transaction. Today&#146;s divestment is consistent
with the company&#146;s strategy to free up capital from <FONT STYLE="white-space:nowrap">non-core</FONT> businesses. The expected Solvency II capital release following the completion of the transaction announced today is approximately
GBP&nbsp;275&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am very pleased that we are able to announce this transaction,&#148; said Alex Wynaendts, CEO of Aegon.
&#147;Achieving the divestment of our UK annuity portfolio is an important step in the strategic repositioning of our business in the United Kingdom. The divestment enables us to fully focus on growing our platform business. At the same time, I am
pleased that we have found in Legal &amp; General a good home for our annuity customers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2010, Aegon chose to no longer be an active player in
the UK annuity market, as it believed these products did not meet Aegon&#146;s long-term risk adjusted return requirements. The divestment of the annuity portfolio significantly reduces Aegon&#146;s exposure to both longevity and credit risk. The
transaction is in line with the company&#146;s continued shift to capital-light businesses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The divestment of the annuity portfolio enables Aegon to
focus on its platform, which helps workplace savers and consumers to build their savings across their working lives, and then manage an income in retirement with the support of a financial adviser or directly online. The UK platform-based pension
market is growing fast, and by repositioning our business, Aegon is in a stronger position to benefit from this growth opportunity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of
the agreement, Aegon will initially reinsure GBP 3 billion of liabilities to Legal &amp; General followed by a Part&nbsp;VII&nbsp;transfer. The Solvency II ratio of Aegon&#146;s operations in the United Kingdom is expected to increase by an
estimated <FONT STYLE="white-space:nowrap">15%-point</FONT> following the reinsurance transaction with Legal &amp; General, and another ~5%-point following the Part VII transfer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aegon expects annual capital generation from its UK operations to be reduced by approximately GBP 30 million (EUR 38 million) as a result of the transaction
announced today. Underlying earnings before tax are expected to be reduced by approximately GBP&nbsp;16&nbsp;million (EUR 20 million) per annum. The reinsurance transaction is expected to result in an IFRS loss of approximately GBP 215 million (EUR
273 million), which will be reported in other charges in the second quarter of 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To ensure a smooth transition for its customers, Aegon and Legal
&amp; General will put a migration plan in place in which the administration of the annuity portfolio will be executed by Aegon until the completion of the Part VII transfer.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Media relations</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Investor relations</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>Debora de Laaf</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Willem van den Berg</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP>+31&nbsp;(0)&nbsp;70&nbsp;344&nbsp;8730</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">+31 (0) 70 344 8405</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" NOWRAP><U>gcc@aegon.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>ir@aegon.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aegon&#146;s roots go back more than 170 years &#150; to the first half of the nineteenth century. Since then, Aegon has grown
into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia. Today, Aegon is one of the world&#146;s leading financial services organizations, providing life insurance, pensions and asset management.
Aegon&#146;s purpose is to help people achieve a lifetime of financial security. More information: <U>aegon.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g187719snap2.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DISCLAIMERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The statements contained in
this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target,
intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, is confident, will, and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and
involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking
statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and
uncertainties include but are not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in general economic conditions, particularly in the United States, the Netherlands and the United Kingdom; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in the performance of financial markets, including emerging markets, such as with regard to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The frequency and severity of defaults by issuers in Aegon&#146;s fixed income investment portfolios; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effects of declining creditworthiness of certain private sector securities and the resulting decline in the value of sovereign exposure that Aegon holds; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in the performance of Aegon&#146;s investment portfolio and decline in ratings of Aegon&#146;s counterparties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consequences of a potential (partial) break-up of the euro or the potential exit of the United Kingdom and/or Greece from the European Union; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The frequency and severity of insured loss events; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes affecting longevity, mortality, morbidity, persistence and other factors that may impact the profitability of Aegon&#146;s insurance products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit markets in general such as changes in borrower and counterparty
creditworthiness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in laws and regulations, particularly those affecting Aegon&#146;s operations&#146; ability to hire and retain key personnel, the products Aegon sells, and the attractiveness of certain products to its
consumers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Regulatory changes relating to the pensions, investment, and insurance industries in the jurisdictions in which Aegon operates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact
on regional (such as EU), national or US federal or state level financial regulation or the application thereof to Aegon, including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII).
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in customer behavior and public opinion in general related to, among other things, the type of products also Aegon sells, including legal, regulatory or commercial necessity to meet changing customer
expectations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Acts of God, acts of terrorism, acts of war and pandemics; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in the policies of central banks and/or governments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lowering of one or more of Aegon&#146;s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegon&#146;s ability to raise capital and on its liquidity and financial
condition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lowering of one or more of insurer financial strength ratings of Aegon&#146;s insurance subsidiaries and the adverse impact such action may have on the premium writings, policy retention, profitability and liquidity of
its insurance subsidiaries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The effect of the European Union&#146;s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">As Aegon&#146;s operations support complex transactions and are highly dependent on the proper functioning of information technology, a computer system failure or security breach may disrupt Aegon&#146;s business,
damage its reputation and adversely affect its results of operations, financial condition and cash flows; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Customer responsiveness to both new products and distribution channels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegon&#146;s products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Changes in accounting regulations and policies or a change by Aegon in applying such regulations and policies, voluntarily or otherwise, which may affect Aegon&#146;s reported results and shareholders&#146; equity;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegon&#146;s ability to integrate acquisitions and to obtain the anticipated results and synergies from
acquisitions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Catastrophic events, either manmade or by nature, could result in material losses and significantly interrupt Aegon&#146;s business; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Aegon&#146;s failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving and excess capital and leverage ratio management initiatives. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and
the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, Aegon expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegon&#146;s expectations with regard thereto or any change in events, conditions or circumstances on which any such
statement is based. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g187719snap1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g187719snap1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M:/95/Y7]P>TAW#_A(]#_ .@S8?\ @2G^-'LJG\K^X/:0[A_PD>A_]!FP_P#
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@#COB;_ ,B>_P#UWC_G75A/XAAB/@/&J]8\\* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * -A?NCZ5) 4 % ';?#;_D)W__ %Q7
M^9KBQGPHZ\)\3/2*\X[PH * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H X[XF_\
M(GO_ -=X_P"==6$_B&&(^ \:KUCSPH * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H V%^Z/I4D!0 4 =M\-O\ D)W_ /UQ7^9KBQGPHZ\+
M\3/2*\X[PH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M%[_W\7_XFCZY4\@^K0#_ (59H7_/Q>_]_%_^)H^N5/(/JT!/^%6:%_S\7O\
MW\7_ .)I_7*GD'U>!9'PYT<#'GW?_?Q?\*7UNIY$_58"_P#"NM'_ .>]W_W\
M7_"CZW4\@^JP#_A76C_\][O_ +^+_A1];J>0?58&IHGABQT&6:2T>9FE4*3(
MP. /H!656M*HK,UITHT]4;58FH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4@"F 4 % !0 4 % !0 4 % !0 4
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M  \<M^M;RPU.,'W,XUIRDM-#TZZUG2[&;R;S4K2WEQG9+.J-CUP37EG80_\
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MQITX*51N[[&?M:E23C22LNK-G1W\2_:G768M/$ 7Y7M6;);Z'M6-3V5O<O\
M,WI^UO[]OD9>I^*-4G\1R:#X=LH9[FW4-<SW#$1Q9Z#CDFM(48*G[2J]'L93
MK3<_9TUJM_(K77B;Q%X<O;3_ (2*SLI-/N9!%]ILRP\MCTR&JHT:55/V;=UT
M9+K5:37M$K/JCN*XCL"F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 ><_$W6-;TE[,6-XUO9W"LK&, -O'^U]#^E=V$A"=^
M9:G-7E*-K'E$LLD\AEFD>60]6=BQ/XFO222T1Q/7<9TI@>Q^"GM_#/AC25NA
MMGU>XX]L@[<_@!^=>573JSE;H=U*T(*_4\Z^)MMI5W\:+.#6Y?)TU[:,3R9P
M57YN_P!<5Q'2:VE^ OA1K.H1V.FZQ-<W3Y98TN#DXY/\- %#4H)OB=\59?#L
MEU)%H>D KL0]0F 3_O$\9/0"D!L^*O@YHL=BLOA>X%AJUN5*"6Y.'YZDGE3W
MR*8$OQ(\2:WX=^'FD:6U^DVL:A^YFN[<X!"_>(/J<@9^M %O2?@?X9CT*.'4
MXYI]1= 99Q*5VL1SM XP/?-%@,/X?7NH>$O&^K> KRX:XM-CO;%OX2%W CT!
M7MZB@#@/ 'B:Y\&>(QJI1_[*FF-M=X'&#R#]1U^F:0'H/Q)DBN/BUX(GB99(
MW\ID<<@@RY!%,#VRF(* "@ H \^\:P7-QXZ\,PVEV;2=A+LF"!MG'H>#7?AF
ME1FVK['#B$W6@D[;FJWASQ/(I1_&4P4\$I:1J?P-9>UI+['XLT]C5_Y^?@B[
MHWANT\-:+=6]L\DTDP:2::4Y:1L=345*TJLTV73I1I0:1F?"[_D0;'_>D_\
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M0?4C)Q2 J_"WPW;>+/!WBO2+G \RX0QR8YC< [6'^>E '*:;-J<?CKPUHNK
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M/]Y@5_(T[4WN+WEL=!8I+'8P+.Y>8(-Y/7/>L)6;=C1;%BD,* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ I
8 )0 4 +0 4 )0 4 % !0 4 % "T ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g187719snap2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g187719snap2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MZZ1_VU_]EKJP7VC+$]#S6O0.,* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H GL_P#CX'T-)B>QHTB0H * /8_"'_(IZ=_US_J:\?$?Q6>I
M0_AHX[XM$#^R/^VO_LM=6"^T98GH>:9'J*] XPR/44 &1ZB@ R/44 &1ZB@
MR/44 &1ZB@ R/44 &1ZB@ R/44 &1ZB@ R/44 &1ZB@ R/44 &1ZB@ R/44
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M *!-E_X#K_A1[6?=AR1[!_PC^C?] FR_\!U_PH]K/NPY(]@_X1_1O^@39?\
M@.O^%'M9]V')'L'_  C^C?\ 0)LO_ =?\*/:S[L.2/8/^$?T;_H$V7_@.O\
MA1[6?=AR1[!_PC^C?] FR_\  =?\*/:S[L.2/8/^$?T;_H$V7_@.O^%'M9]V
M')'L'_"/Z-_T";+_ ,!U_P */:S[L.2/8/\ A']&_P"@39?^ Z_X4>UGW8<D
M>P?\(_HW_0)LO_ =?\*/:S[L.2/8/^$?T;_H$V7_ (#K_A1[6?=AR1[!_P (
M_HW_ $";+_P'7_"CVL^[#DCV#_A']&_Z!-E_X#K_ (4>UGW8<D>P?\(_HW_0
M)LO_  '7_"CVL^[#DCV#_A']&_Z!-E_X#K_A1[6?=AR1[!_PC^C?] FR_P#
M=?\ "CVL^[#DCV!=!T=3E=*LP?:!?\*/:S[L.2/8?_8NE?\ 0,M/^_*_X4>T
MGW8>SAV#^Q=*_P"@9:?]^5_PH]I/NP]G#L)_8NE?] RT_P"_*_X4>TGW8>SA
MV+D<20QK'$BHBC 51@ 5#;>K+6FB'T % !0 4 % !0 4 % !0 4 % !0 4 %
M(! P)(!&1U'I3 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * *=_JNGZ7%YE]>0VZ_[;@$_A51A*7PH3DH[G&:I\5M*M<IIUO+>
MOV8_(GZ\G\JZX8.;^+0PEB(K;4XG5?B+XAU+<J7*V41_AMQ@_P#?1YKKAA:<
M>ESGE7F_(Z_X=:+KNGW3ZA>$/9W\ ;+REGSU4D'V)KEQ52G)<JW1O1C..KZD
M<_QQ\)6UQ+!(FH!XG9#B 8R#@_Q5P'4:'AWXL^&_$^N0Z1IZW@N9@Q7S(@J\
M#)YS0!'XH^+OAOPS?OIY,U]>1G$D=N 0A]"QXS["@"UX2^)WA[Q?<?8[622V
MOL9%O< *6QUVGH?YT ;'B;Q;H_A&P6[U>Y\L.<1QH-SR'_9% CC-/^.GA>[O
M5@N8;RRC8X6:5 4^IP<@4#.R\1^+-,\,:$FLWK22V;LJJUNH<MNZ$<]* +>@
MZY8^(]&M]4TZ0O;3C(R,,I[@CL10(S/#GCC2?%&J:CIVGK<"?3VVS>;&%&<D
M<'//(- SI:8@H * "@ H * "@ H * "@ H * "@ H *0'@WQ TY]/\8W>XL4
MN,31ECG@]0/Q!KVL-+FIH\^M&TSF*Z#$NZ/I[:KK-G8+_P MY0I]AW/Y9J)R
MY(N14(\TDCV^P\0Q/XRN_#R!5BMK=#'C^\/O#\BM>1*DU353N>@I^^X'@WA3
MQ-8>%=?\0#4_#SZJ9KA@J^6K>40[9Z@XSG]*YC4]+T_QAIE_X*\0:_I?AM=*
MNM.B98V:%5;<5X(('O3 S_@GH&G1^%KKQ+>PI/>2S2#S9%W%$7KCW)R30@*5
MYJ_PNUWQEINM0:C<VMY'(N$MH&C$KY&TL<?_ *^] #9K>/QE^T'/9:H/.LM-
M0[(6Y4[0#C'H6;)^E 'I/C3PKIFN^$[VTFM85:.%G@D5 #$P&01Z=* /#$U>
MXO\ X!SVL[%Q8:G''&2>B$;@/PR:0&[\,]:N_ _B.UT+57QI>MQ1W%M(?NJ[
M#@^V?NGW H0&K\&^/'?C(?\ 37_VH]- >TTQ!0 4 % !0 4 % !0 4 % !0
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M))+KWB%YBQE:*,N6Z[MS9S[T(#W>F(* "@ H * "@ H * "@ H * "@ H *
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MUD!'0CM0(GBM;>!V>&".-F^\44 GZT 2TP"@ H * "@ H * "@ H * "@ H
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M * "@ H * "@ H * "@ H * "@ H * "@!*0!0,* %H$)0 4 '>@84""@ H
&* %I@?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
